Rep. Lois Frankel sold Charles River Laboratories International (CRL)
Rep. Lois Frankel (D-FL-22) · $1K–$15K · traded Sep 8, 2023
- Transaction
- Sold
- Amount
- $1K–$15K
- Owner
- Not stated
- Traded
- Sep 8, 2023
- Disclosed
- Oct 10, 2023
- Days to disclose
- 32
- Asset type
- Stock
- As filed
- Charles River Laboratories International, Inc.
- Industry
- Medical - Diagnostics & Research · Healthcare
Other trades in this filing
All of Frankel's trades →- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
Sold First American Financial FAF
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
Sold The Sherwin-Williams Company SHW
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
Sold Booz Allen Hamilton Holding BAH
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
Sold Broadridge Financial Solutions BR
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$15K–$50K
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$15K–$50K
$15K–$50K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$15K–$50K
$15K–$50K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- Oct 10, 2023$1K–$15K
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
Recent Congress trades in CRL
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Sold Charles River Laboratories International CRL
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Bought Charles River Laboratories International CRL
$15K–$50K · Traded May 8, 2025 · disclosed Jun 22, 2025
- May 31, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
Sold Charles River Laboratories International CRL
$1K–$15K · Traded May 15, 2025 · disclosed May 31, 2025
- May 8, 2025$15K–$50K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
Bought Charles River Laboratories International CRL
$15K–$50K · Traded Apr 8, 2025 · disclosed May 8, 2025
- Feb 12, 2025$1K–$15K
Rep. Julie Johnson (D-TX-32)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Dec 5, 2024$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Nov 15, 2024 · disclosed Dec 5, 2024
- Nov 8, 2023$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Oct 2, 2023 · disclosed Nov 8, 2023
- May 19, 2023$1K–$15K
Rep. Lois Frankel (D-FL-22)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Apr 25, 2023 · disclosed May 19, 2023
Company context for CRL
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
CRL: third_quarter 2026 lobbying report
Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues surrounding improvements to clinical research capabilities and modernization of research methods.
Public: Oct 20, 2026, 9:28 PM EDTOriginal source ↗CRL: second_quarter 2026 lobbying report
Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues surrounding improvements to clinical research capabilities and modernization of research methods.
Public: Jul 20, 2026, 10:36 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.